Under the agreements, BioSig plans to establish a new product pipeline for its Pure EP system for acquiring, digitizing, measuring, displaying and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures.
The new research and development pipeline is slated to include hardware, software and algorithmic solutions for the technology. BioSig said it intends to lead its licensed products, which Mayo Clinic has developed over the last decade, through the approval, manufacturing and commercialization processes.
According to a news release, Mayo Clinic plans to use any revenue it receives from BioSig’s technologies to support its not-for-profit mission in patient care, education and research.
Mayo Clinic, having already worked together with BioSig for two years, invested $1 million in the company in July. In September, BioSig signed a new licensing agreement with Mayo Clinic to further its Pure EP system. The two entities had already inked a 10-year strategic partnership agreement for the Pure EP system’s development in March 2017 before BioSig opened a Rochester, Minn. technology development office in collaboration with Mayo Clinic.
“Sustainable innovation in medicine goes beyond individual products and entails consistent approach to improving the way therapies are delivered,” BioSig chairman & CEO Kenneth Londoner said in the release. “A significant part of our R&D efforts is dedicated to basic science to advance understanding of arrhythmia origination and analysis of the spectrum of other conditions which often accompany heart disease. Mayo Clinic’s mission to providing the best care through integrated clinical practice, research and education deeply resonates with BioSig’s own mission to lead through innovation in bioelectronic medicine, and we are pleased to unveil this new, exciting, chapter in our company’s development.”
“Development of leading-edge therapeutic solutions requires profound knowledge of the leading academic institutions and commitment and dedication of the industry,” added Mayo Clinic electrophysiology laboratory vice chair of innovation & medical director Dr. Samuel Asirvatham. “As part of the growing relationship between physicians at Mayo Clinic and BioSig, my colleagues and I look forward to contributing to the success of the new projects.”